{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:14:56Z","timestamp":1793297696832,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"The National Institute for Health Research Biomedical Research Centre for cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108315","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:18:26Z","timestamp":1786378706000},"page":"108315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2643-2196","authenticated-orcid":false,"given":"A.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Satchwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-9120","authenticated-orcid":false,"given":"S.","family":"Cromarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Piadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Zhitkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Terlizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-6790","authenticated-orcid":false,"given":"P.","family":"Proszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pietka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Peat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3537-8612","authenticated-orcid":false,"given":"E.","family":"Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2976-4410","authenticated-orcid":false,"given":"P.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sothi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4539-0001","authenticated-orcid":false,"given":"R.","family":"Herbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-3829","authenticated-orcid":false,"given":"T.","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"I.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"D.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.esmoop.2026.108315_bib1","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108315_bib4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10294","key":"10.1016\/j.esmoop.2026.108315_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108315_bib6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"10389","key":"10.1016\/j.esmoop.2026.108315_bib7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"9742","key":"10.1016\/j.esmoop.2026.108315_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108315_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7636","key":"10.1016\/j.esmoop.2026.108315_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Nature"},{"issue":"7517","key":"10.1016\/j.esmoop.2026.108315_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108315_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108315_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol Cell"},{"issue":"30","key":"10.1016\/j.esmoop.2026.108315_bib14","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1038\/onc.2013.352","article-title":"Predictive biomarkers for cancer therapy with PARP inhibitors","volume":"33","author":"Michels","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","article-title":"Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective","volume":"46","author":"Sandhu","year":"2010","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108315_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2026.108315_bib17","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7035","key":"10.1016\/j.esmoop.2026.108315_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.esmoop.2026.108315_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108315_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108315_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 Study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108315_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108315_bib23","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108315_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108315_bib25","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2026.108315_bib26","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108315_bib27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108315_bib28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108315_bib29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2026.108315_bib30","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10106","key":"10.1016\/j.esmoop.2026.108315_bib31","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108315_bib32","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108315_bib33","article-title":"Maintenance capecitabine plus ramucirumab after first-line chemotherapy in patients with advanced esophagogastric adenocarcinoma: results from the randomized PLATFORM study","volume":"2","author":"Gordon","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108315_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103622","article-title":"Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study","volume":"9","author":"Fong","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108315_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41416-026-03448-4","article-title":"Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial","volume":"135","author":"Gordon","year":"2026","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108315_bib36","article-title":"GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles","volume":"4","author":"Pozzorini","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.esmoop.2026.108315_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103503","article-title":"3P The validation of a homologous recombination deficiency assay into clinical practice within the NHS","volume":"9","author":"Ratsma","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108315_bib39","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108315_bib40","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108315_bib41","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-23-1467","article-title":"The clinical implications of reversions in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, or PALB2 after progression on rucaparib","volume":"29","author":"Brown","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108315_bib42","doi-asserted-by":"crossref","first-page":"13145","DOI":"10.1002\/cam4.5997","article-title":"Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results","volume":"12","author":"Ciardiello","year":"2023","journal-title":"Cancer Med"},{"issue":"33","key":"10.1016\/j.esmoop.2026.108315_bib43","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108315_bib44","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108315_bib45","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S1470-2045(24)00580-1","volume":"25","author":"Randon","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108315_bib46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib47","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/s41467-026-69622-7","article-title":"First-line modified FOLFOX plus\/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial","volume":"17","author":"Lorenzen","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108315_bib48","doi-asserted-by":"crossref","first-page":"8683","DOI":"10.1038\/ncomms9683","article-title":"A mutational signature in gastric cancer suggests therapeutic strategies","volume":"6","author":"Alexandrov","year":"2015","journal-title":"Nat Commun"},{"issue":"94","key":"10.1016\/j.esmoop.2026.108315_bib49","doi-asserted-by":"crossref","first-page":"36654","DOI":"10.18632\/oncotarget.26336","article-title":"Genomic loss of heterozygosity and survival in the REAL3 trial","volume":"9","author":"Smyth","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt335","article-title":"Identification and validation of an anthracycline\/cyclophosphamide\u2013based chemotherapy response assay in breast cancer","volume":"106","author":"Mulligan","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"36","key":"10.1016\/j.esmoop.2026.108315_bib51","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.19.00693","article-title":"Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c Trial","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108315_bib52","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1136\/gutjnl-2018-317624","article-title":"Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma","volume":"68","author":"Turkington","year":"2019","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108315_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103450","article-title":"An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma","volume":"9","author":"Baxter","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108315_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108315_bib55","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u201cBRCAness\u201d in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108315_bib56","first-page":"821","article-title":"Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression","volume":"15","author":"Hanazono","year":"2006","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108315_bib57","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.3390\/ijms26104644","article-title":"ARID1A and its impact across the hallmarks of cancer","volume":"26","author":"Kearns","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108315_bib58","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108315_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","article-title":"Genetic predictors of response to systemic therapy in esophagogastric cancer","volume":"8","author":"Janjigian","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108315_bib60","article-title":"Single agent olaparib in advanced oesophago-gastric cancer: primary results from the SOlar clinical phase II single arm trial","volume":"43","author":"Keogh","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602257X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602257X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:40:15Z","timestamp":1792770015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602257X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S205970292602257X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108315","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance rucaparib after first-line platinum-based chemotherapy in HER2-negative advanced oesophagogastric adenocarcinoma: results from the PLATFORM study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108315"}}